Transcriptome-based antigen identification for Neisseria meningitidis

Vaccine

Volumn 21, Issue 7-8, 2003, Pages 768-775

  Kurz, Sebastian ^a   Hübner, Claudia ^a   Aepinus, Christian ^a   Theiss, Stephanie ^a   Guckenberger, Matthias ^a   Panzner, Ursula ^a   Weber, Jacqueline ^b   Frosch, Matthias ^a   Dietrich, Guido ^a,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b MWG Biotech AG   (Germany)

^c Berna Biotech AG   (Switzerland)

Author keywords

Antigen screening; DNA microarrays; Meningococci; Serogroup B; Transcriptome analysis

Indexed keywords

BACTERIAL ANTIGEN; EPITOPE; GENOMIC DNA; MENINGOCOCCUS VACCINE;

ANTIGEN EXPRESSION; B LYMPHOCYTE; BACTERIAL STRAIN; CONFERENCE PAPER; DATA ANALYSIS; DNA MICROARRAY; ENDOTHELIUM CELL; EPITHELIUM CELL; GENETIC TRANSCRIPTION; IMMUNOGENICITY; MENINGOCOCCOSIS; METHODOLOGY; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEROTYPE; T LYMPHOCYTE;

ANTIGENS, BACTERIAL; ANTIGENS, SURFACE; BACTERIAL ADHESION; CELL LINE; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTION, GENETIC;

EID: 0037472386     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00596-0     Document Type: Conference Paper

References (32)

1. Connolly M., Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-1996. Epidemiol. Infect. 122:1999;41-49.
2. Morley S.L., Pollard A.J. Vaccine prevention of meningococcal disease, coming soon? Vaccine. 20:2002;666-687.
3. Ala'Aldeen D.A., Cartwright K.A. Neisseria meningitidis: vaccines and vaccine candidates. J. Infect. 33:1996;153-157.
4. Ramsay M.E., Andrews N., Kaczmarski E.B., Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 357:2001;195-196.
5. Pizza M., Scarlato V., Masignani V.et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 287:2000;1816-1820.
6. Frosch M., Görgen I., Boulnois G.J., Timmis K.N., Bitter-Suermann D. NZB-mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc. Natl. Acad. Sci. U.S.A. 82:1985;1194-1198.
7. Poolman J.T., Hopman C., Zanen H. Immunogenicity of meningococcal surface antigens as detected in patient sera. Infect. Immun. 40:1983;398-406.
8. Bjune G., Hoiby E.A., Gronnesby J.K.et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 338:1991;1093-1096.
9. de Moraes J.C., Perkins B.A., Camargo M.C.et al. Protective efficacy of a serogroup B meningococcal vaccine in São Paulo, Brazil. Lancet. 340:1992;1074-1078.
10. Cartwright K., Morris R., Rumke H.et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine. 17:1999;2612-2619.
11. Parkhill J., Achtman M., James K.D.et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature. 404:2000;502-506.
12. Tettelin H., Saunders N.J., Heidelberg J.et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 287:2000;1809-1815.
13. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 19:2001;2688-2691.
14. Frosch M., Meyer T.F. Transformation-mediated exchange of virulence determinants by co-cultivation of pathogenic Neisseriae. FEMS Microbiol. Lett. 79:1992;345-349.
15. Hammerschmidt S., Muller A., Sillmann H.et al. Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol. Microbiol. 20:1996;1211-1220.
16. Saunders N.J., Jeffries A.C., Peden J.F.et al. Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol. Microbiol. 37:2000;207-215.
17. Sun Y.H., Bakshi S., Chalmers R., Tang C.M. Functional genomics of Neisseria meningitidis pathogenesis. Nat. Med. 6:2000;1269-1273.
18. Stephens D.S., Farley M.M. Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev. Infect. Dis. 13:1991;22-33.
19. Cartwright K.A., Ala'Aldeen D.A. Neisseria meningitidis: clinical aspects. J. Infect. 34:1997;15-19.
20. Virji M., Kayhty H., Ferguson D.J.P., Heckels J.E., Moxon E.R. The role of pili in the interactions of pathogenic Neisseria with cultured human endothelial cells. Mol. Microbiol. 5:1991;1831-1841.
21. Guckenberger M., Kurz S., Aepinus C.et al. Analysis of the heat shock response of Neisseria meningitidis with cDNA- and oligonucleotide-based DNA microarrays. J. Bacteriol. 184:2001;2546-2551.
22. Dietrich G, Kurz S, Hübner C, et al. Transcriptome analysis of Neisseria meningitidis during infection, in press.
23. Osicka R., Kalmusova J., Krizova P., Sebo P. Neisseria meningitidis RTX protein FrpC induces high levels of serum antibodies during invasive disease: polymorphism of frpC alleles and purification of recombinant FrpC. Infect. Immun. 69:2001;5509-5519.
24. Larson J.A., Higashi D.L., Stojiljkovic I., So M. Replication of Neisseria meningitidis within epithelial cells requires TonB-dependent acquisition of host cell iron. Infect. Immun. 70:2002;1461-1467.
25. Schryvers A.B., Stojiljkovic I. Iron acquisition systems in the pathogenic Neisseria. Mol. Microbiol. 36:1999;1117-1123.
26. Scheuerpflug I., Rudel T., Ryll R., Pandit J., Meyer T.F. Roles of PilC and PilE proteins in pilus-mediated adherence of Neisseria gonorrhoeae and Neisseria meningitidis to human erythrocytes and endothelial and epithelial cells. Infect. Immun. 67:1999;834-843.
27. Johnson A.S., Gorringe A.R., Mackinnon F.G., Fox A.J., Borrow E., Robinson A. Analysis of human Ig isotype response to lactoferring binding protein A from Neisseria meningitidis. FEMS Immunol. Med. Microbiol. 25:1999;349-354.
28. Ala'Aldeen D.A., Davies H.A., Borriello S.P. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine. 12:1994;535-541.
29. Brooks G.F., Lammel C.J., Blake M.S., Kusecek B., Achtman M. Antibodies against IgA1 protease are stimulated both by clinical disease and asymptomatic carriage of serogroup A Neisseria meningitidis. J. Infect. Dis. 166:1992;1316-1321.
30. Martin D., Cadieux N., Hamel J., Brodeur B.R. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 185:1997;1173-1183.
31. Farrant JL, Kroll SJ, Brodeur BR, Martin D. Detection of anti-NspA antibodies in sera from patients convalescent after meningococcal infection. In: Nassif X, Quentin-Millet M-J, Taha M-K, editors. Proceedings of the 11th International Pathogenic Neisseria Conference, Nice, France, 1998. p. 208.
32. Pettersson A., Poolman J.T., van der Ley P., Tommassen J. Response of Neisseria meningitidis to iron limitation. Antonie Van Leeuwenhoek. 71:1997;129-136.